Ontology highlight
ABSTRACT: Introduction
Heart rate slowing agents are frequently prescribed to manage heart transplant (HTx) patients with the assumption that higher heart rate is a risk factor in cardiovascular disease.Patients and methods
This prospective two-center study investigated early progression of cardiac allograft vasculopathy (CAV) in 116 HTx patients. Examinations by coronary optical coherence tomography and 24-hour ambulatory ECG monitoring were performed both at baseline (1 month after HTx) and during follow-up (12 months after HTx).Results
During the first post-HTx year, we observed a significant reduction in the mean coronary luminal area from 9.0 ± 2.5 to 8.0 ± 2.4 mm2 (P < .001), and progression in mean intimal thickness (IT) from 106.5 ± 40.4 to 130.1 ± 53.0 µm (P < .001). No significant relationship was observed between baseline and follow-up mean heart rates and IT progression (R = .02, P = .83; R = -.13, P = .18). We found a mild inverse association between beta-blocker dosage at 12 months and IT progression (R = -.20, P = .035).Conclusion
Our study did not confirm a direct association between mean heart rate and progression of CAV. The role of beta blockers warrants further investigation, with our results indicating that they may play a protective role in early CAV development.
SUBMITTER: Pazdernik M
PROVIDER: S-EPMC7220813 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Pazdernik Michal M Wichterle Dan D Chen Zhi Z Bedanova Helena H Kautzner Josef J Melenovsky Vojtech V Karmazin Vladimir V Malek Ivan I Stiavnicky Peter P Tomasek Ales A Ozabalova Eva E Krejci Jan J Wahle Andreas A Zhang Honghai H Kovarnik Tomas T Sonka Milan M
Clinical transplantation 20200109 2
<h4>Introduction</h4>Heart rate slowing agents are frequently prescribed to manage heart transplant (HTx) patients with the assumption that higher heart rate is a risk factor in cardiovascular disease.<h4>Patients and methods</h4>This prospective two-center study investigated early progression of cardiac allograft vasculopathy (CAV) in 116 HTx patients. Examinations by coronary optical coherence tomography and 24-hour ambulatory ECG monitoring were performed both at baseline (1 month after HTx) ...[more]